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Abstract
Objective. SSc is clinically and aetiopathogenically heterogeneous. Consensus standards for more
uniform trial design and selection of outcome measures are needed. The objective of this study was to
develop evidence-based points to consider (PTCs) for future clinical trials in SSc.
Methods. Thirteen international SSc experts experienced in SSc clinical trial design were invited to par-
ticipate. One researcher with experience in systematic literature review and three trainees were also
included. A systematic review using PubMed and the Cochrane Central Register of Controlled Trials
was conducted and PTCs when designing clinical trials in SSc were developed. As part of that develop-
ment we conducted an Internet-based Delphi exercise regarding the main points to be made in the
consensus statement. Consensus was defined as achieving a median score of 57 of 9.
Results. By consensus, the experts decided to develop PTCs for each individual organ system. The
current document provides a unifying outline on PTCs regarding general trial design, inclusion/exclusion
criteria and analysis. Consensus was achieved regarding all the main points of the PTCs.
Conclusion. Using European League Against Rheumatism suggestions for PTCs, a general outline for
PTCs for controlled clinical trials in SSc was developed. Specific outlines for individual organ systems are
to be published separately. This general outline should lead to more uniform and higher-quality trials and
clearly delineate areas where further research is needed.
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Introduction
SSc is clinically and aetiopathogenically heterogeneous
[1]. Among the many different immune-mediated rheum-
atic diseases, SSc stands out as a severely incapacitating
and life-threatening disease for which therapeutic options
are few and insufficient.
Recent years have seen important refinements in the de-
velopment and validation of candidate outcome measures
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[2, 3] and increased sophistication in trial methodology in
SSc [4]. This is paralleled by an increased understanding of
the pathogenesis of SSc [5, 6] and thus the possibility to
develop more targeted therapies [7, 8]. Controlled trials
may target constitutive elements of the disease process
(e.g. vasculopathy, fibrosis, immune activation) or might
focus on more narrow clinical outcomes [e.g. digital
ulcers, interstitial lung disease (ILD)]. This complexity hin-
ders comparisons between trials and contributes to delay in
evaluating the most appropriate therapeutics for this dis-
ease. Under the auspices of the European League Against
Rheumatism (EULAR), we undertook the task of developing
points to consider (PTCs) for conducting clinical trials in
SSc [9] using a combination of research-based evidence
and expert consensus.
Methods
Expert committee members
The steering committee consisted of 13 experts in the
field of SSc. In addition, three trainees and one method-
ologist were recruited for the systematic reviews
(discussed below). We also sought input from experts in
cardiopulmonary and lung involvement in SSc.
Current and past trials have approached SSc within one
of the following constructs: (i) overall survival, (ii) specific
organ-based complications and (iii) measures of compos-
ite response including several related disease features. An
agent with putative antifibrotic effects might reasonably
target clinical features thought to represent tissue fibrosis
(e.g. skin and parenchymal lung involvement), but effects
might not be measurable in patients with very mild expres-
sion of these disease features. An agent with putative
antivascular effects might reasonably target clinical fea-
tures thought to represent vascular complications (e.g.
digital ulceration or pulmonary vascular syndromes), but
might permit the study of broader populations. These ex-
amples of heterogeneity of disease expression provide
part of the rationale for consideration of organ-specific
PTCs.
In SSc, clinical trials for each organ system have their
own particular requirements [2, 10]. In addition, and be-
cause there are significantly different issues to consider
among the various organs potentially affected in SSc, the
experts decided to approach SSc based on individual
organ systems against a background of a general, unifying
approach. The present statement represents the discus-
sion of the general unifying approach.
The 11 specific organ systems or aspects to be con-
sidered will be published elsewhere and will include car-
diac, renal, digital ulcers, gastrointestinal, health-related
quality of life and functional disability, joints, muscle, pul-
monary fibrotic, pulmonary vascular, RP and skin
involvement.
Structured search strategy
We wished to have an appropriate literature background
and evidence base for our considerations. Thus We did a
systematic literature review using PubMed and the
Cochrane Central Register of Controlled Trials. We exam-
ined the literature between 1995 (the time of the publica-
tion of the previous guidelines) and January 2011. The
only exceptions were the organ systems of muscles and
joints, where we examined the literature from 1966 to
2011 because there were very few articles that met our
search strategy in these areas since 1995. Further, the
bibliographies of all articles unearthed by our search strat-
egy were reviewed for additional articles.
All articles that were clinical trials in SSc and were in
English were included, with the following exclusions:
animal studies; not concerned with humans; not pertain-
ing to SSc; not a casecontrol study, case series, cohort
study, database or registry; not pertaining to instruments
or diagnostic tests; editorial, review article, letter or opin-
ion; pertaining to infants or children; genetic studies (i.e.
polymorphisms, genetic associations with internal organs,
etc.). We obtained 4901 titles and ultimately extracted 903
titles as our evidence-based literature. These articles were
the basis for both the present, general PTC discussions
and for the organ-specific PTCs.
The PTCs were drafted, considered and revised by all
authors. The principle points themselves were subjected
to a Delphi exercise done on the Internet. Although the
first round achieved consensus (median scores of 57 of
9, where 9 was totally appropriate) on all statements, a
second round was undertaken for all questions for which
at least one participant gave a score of 13 or at least two
participants gave a score of 46.
Many of the PTCs are based on evidence from general
clinical science in SSc. When specific references
are available, they are cited. The statements are labelled
according to the quality of the evidence supporting
them, using the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) System [11].
Quality of evidence
The following definitions were used:
High quality: further research is very unlikely to change
confidence in the statement.
Moderate quality: further research is likely to have an
important impact on confidence in the statement and
may change the statement.
Low quality: further research is very likely to have an
important impact on confidence in the statement
and is likely to change the statement.
Very low quality: any statement is very uncertain.
Results
Table 1 outlines the questions and median scores after the
second, and final, Delphi round.
General design
There was clear consensus that clinical trials in SSc
should adhere to the general approach supported by the
US Food and Drug Administration (FDA; http://www.fda.
gov) and the European Medicines Agency (http://www.
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ema.europa.eu/docs/en_GB/document_library/Scientific_
guideline/2009/09/WC500002874.pdf) for good clinical
practice. These guidelines indicate that
(i) All trials should be well controlled, meaning, in general,
that they should be randomized, blinded and controlled,
particularly when undertaking phase 2 or phase 3 trials
(high quality).
There are other considerations, however, and there are
some nuances. Non-randomized trials could be con-
sidered in the very earliest phases of therapeutic develop-
ment, although, even here, some experts felt that
randomization is the most appropriate approach (low
quality).
While trials could be open label, a clear consensus for
blinding, either single or double, was found, as the biases
TABLE 1 Results of the Delphi exercise on points to consider for clinical trials in SSc
Result of the Delphi exercise on points to consider for clinical trials in SSc Median
All trials should be well controlled, meaning, in general, that they should be
randomized, blinded and controlled, particularly when undertaking phase 2 or
phase 3 trials
9
Non-randomized trials should only be considered in the very earliest phases of
therapeutic development, although, even here, randomization may be the
most appropriate approach
8
While trials could be open label, blinding, either single or double, is most
appropriate
9
In general, placebo-controlled trials, allowing appropriate background therapy,
are strongly favoured
8
It was agreed that when effective therapies for a given organ system are
available, positively controlled trials can be considered
8
Trial duration is often a critical consideration and should be tailored for the
specific medication and organ system manifestation
9
Biologic response trials may be particularly short, although clinical correlations
are highly desirable
8
Ethical considerations need to be adhered to 9
The CONSORT guidelines are an appropriate outline for reporting clinical trials 9
Biosampling should be done whenever possible 8
Obvious considerations in designing clinical trials include gender, age and
disease subsets
8
Most trials of therapeutic interventions in SSc are initially done in adults 9
Testing of medications in children may be required and important, so trials in
the young should be considered at some point
8
Trials in scleroderma should generally be done in uniform disease subsets (e.g.
diffuse, limited or diffuse/limited)
8
Generally patients with well-defined overlapping diseases should be excluded
from SSc clinical trials
8
Disease duration needs to be considered 9
Well-defined SSc should be one of the inclusion criteria 9
Environmental exposure to substances that have been associated with
scleroderma-like disease (e.g. vinyl chloride, trichloroethylene, silica dust)
should be excluded so that a uniform group of patients is tested
8
Concomitant medications need to be carefully considered when defining a trial
in SSc
9
Concomitant diseases need to be considered when defining a trial in SSc 9
The primary outcome measure should be a validated measure 8
If the contemplated primary outcome has not been validated, it might be pru-
dent to develop or test such validation as a preliminary to a phase 3 trial
8
Other organ system manifestations that might confound the primary outcome or
might result in dropout before study completion should be considered
9
When analysing a clinical trial, prespecified analyses are important 9
The patient population needs to be described in sufficient detail so that one is
able to understand the type of patient for whom the intervention would be
applicable
9
Depending on the phase of the study, power analysis to define the number of
patients needed to have confidence in the results is appropriate
9
Power analyses are not always necessary if the result is aimed at understanding
future study design or getting a sense of the safety of a treatment
8
Statistical tests should consider the distribution of results (e.g. parametric
versus non-parametric distributions), characteristics of the outcomes (con-
tinuous, ordinal, dichotomous) and how to deal with the inevitable missing
results (a strategy to account for missing data)
9
How to summarize and examine adverse events should be considered 9
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in open trials have, in the past, led to incorrect conclu-
sions (high quality). Examples are D-penicillamine, colchi-
cine and dimethyl sulphoxide (DMSO) [1214]. Some
experts felt that single blinding and open studies might
be appropriate under specific circumstances where
double or single blinding might be impossible (e.g. when
a therapeutic intervention could not be blinded, such as
acupuncture and stem cell transplantation). Even here,
attempts at blinding should be made, such as using a
blinded observer while a non-blinded investigator cares
for the patient or overviews laboratory tests that might
unblind the study.
(ii) In general, placebo-controlled trials, allowing appropri-
ate background therapy, were favoured (moderate qual-
ity). Because SSc can be such a severe and progressive
disease, there was some sentiment for positively
controlled trials. It was agreed that when effective thera-
pies for a given organ system are available, positively
controlled trials should be considered (high quality). An
example of such an instance is the use of CYC for ILD;
in this subset of patients, a positively controlled trial has,
in fact, been undertaken and showed short-term efficacy
(18 months) [15]. However, 2 year follow-up data of CYC
questioned its long-term benefits and issues of statistical
power and statistical non-inferiority may make positively
controlled trials difficult to conduct in a disease in which
the prevalence and incidence is low.
Trial duration
(iii) Trial duration is often a critical consideration (moderate
quality). Selecting a trial duration that is too short may
yield an inappropriate negative result despite the tempta-
tion to keep trials short for both time and cost consider-
ations. On the other hand, choosing a trial duration that is
too long (particularly if placebo controlled) may be ethic-
ally questionable. Some trial durations can be particularly
short (e.g. 6 weeks) if all that is being examined is a bio-
logical response, although such a response without clin-
ical correlation may be of very limited use. Trial duration
can sometimes be derived from an examination of the
literature. For example, a 12 week trial might be appropri-
ate for RP and is supported by the literature [16]. A 12- to
16-week trial would be more appropriate for testing pul-
monary hypertension, while 1624 weeks may be appro-
priate for testing haemodynamic changes in pulmonary
hypertension prevention and healing of digital ulcers,
again supported by the literature [17, 18]. Longer trials
of 624 months may be necessary to prove an effect on
remodelling and fibrotic outcomes such as in ILD or on
skin fibrosis [1922].
Ethical considerations
(iv) Ethical aspects need to be considered, which is a given
(high quality). In addition, the Consolidated Standards of
Reporting Trials (CONSORT) guidelines were accepted as
an appropriate outline for reporting clinical trials (moderate
quality) [23].
Biosampling
Our understanding of the pathogenesis of SSc is incom-
plete and better treatments are clearly needed. In that
context it was agreed that
(v) Biosampling should be done whenever possible, as
such sampling allows exploring new pathways or new
treatments and validating biomarkers (low quality). While
it was understood that there may be barriers to biosam-
pling, such as the difficulty with storage or transportation
and human subject protection issues, it was also clear
that results in other connective tissue diseases could
not necessarily be transposed to SSc. Thus biosampling
according to good laboratory and clinical practice with
respect to collection, storage and distribution should be
considered in any trial and is encouraged. Such guidelines
have been proposed and include serum, plasma, cellular
and biological samples such as skin or lung [24].
Inclusion/exclusion criteria
(vi) A major issue in clinical trials is choosing appropriate
and uniform patient groups. Uniformity in patient groups
improves the likelihood of a clear outcome (high quality).
At the same time, uniformity may decrease the generaliz-
ability of the results.
(vii) Well-defined SSc should be one of the inclusion cri-
teria (high quality). However, this may require some
thought. There are, for example, several definitions of
SSc, including the preliminary 1980 ACR criteria and
new criteria attempting to define the disease at an earlier
stage [2527]. These may result in very different popula-
tions of patients and may make it difficult to compare pa-
tient groups across different trials. At the present time,
most trials use the 1980 ACR criteria. If one wishes to
consider more than one set of diagnostic criteria, it
might be best to define one set of criteria as the primary
one while analysing the trial in an exploratory manner in
terms of other criteria. In this way, cross-trial comparisons
can still be made.
Scleroderma can be classified as a systemic disease, with
subsets of diffuse and limited cutaneous disease, overlap
disease and non-systemic localized disease. Many SSc
trials are done in SSc patients with diffuse disease be-
cause outcome measures have only been validated in
the diffuse cutaneous disease subset. On the other
hand, when considering various visceral involvements,
both limited cutaneous and diffuse cutaneous disease
might be appropriate. The latter is true, for example,
when testing ILD or pulmonary arterial hypertension.
Likewise, many patients have an overlap with other dis-
eases such as RA, polymyositis or SLE. While including
overlap patients will increase recruitment, the inclusion of
patients with multiple diseases will likely confound any
potential therapeutic benefit and might also result in ad-
verse effects that are not seen in patients with pure SSc.
(viii) Other considerations include gender, age and
disease duration (high quality). Gender considerations
must include the fact that SSc is more frequent in
www.rheumatology.oxfordjournals.org 147
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women, so both men and women will clearly need to be
recruited. Pregnancy and fertility considerations are ne-
cessary for both men and women when seeking to do a
trial in SSc. Breastfeeding subjects should generally be
excluded as medications can be transported in breast
milk in unknown amounts, thus exposing infants without
appropriate knowledge of the medication’s safety in in-
fants. When such knowledge has been gained, limited
studies in breastfeeding mothers may be considered.
(ix) Most trials of therapeutic interventions in SSc are ini-
tially done in adults, as the therapies may adversely affect
growth, development and fertility, thus contraindicating
their use in children (moderate quality). On the other
hand, testing of medications in children may be required
and is important, so trials in the young should be con-
sidered at some point. If the therapeutic intervention
does not have an adverse potential in children (e.g. a
physical therapy intervention), trials in children should be
encouraged.
(x) Disease duration needs to be considered in terms of
the definition of disease duration. Some believe that dur-
ation should be defined based on the first symptom or
sign, such as RP; others feel that, because RP may
occur many years before the next sign or symptom, dur-
ation should be from the first typical sign or symptom
other than RP [15]. This has major implications because
the duration of disease is thought by most to help define
the likelihood of response to specific therapies. Early dis-
ease (35 years) changes rapidly and thus therapeutic
change can be discerned in a relatively short period of
time (e.g. 1 year), while late disease may change slowly
and may require much longer trials. In general, most trials
define disease duration from the first non-RP sign or
symptom.
(xi) In general, environmental exposure to substances that
have been associated with scleroderma-like disease (e.g.
vinyl chloride, trichloroethylene, silica dust) should be
excluded. These should be excluded by history so that a
uniform group of patients is tested (moderate quality).
While one might argue that targeting scleroderma-like dis-
ease might be desirable, the lack of understanding of how
these external environmental stimulations result in disease
make it unlikely that such a choice would be prudent.
(xii) Concomitant medications need to be carefully con-
sidered when defining a trial in SSc (high quality). It would
be ethically inappropriate to insist on allowing no
concomitant medication and it would also make recruit-
ment impossible. On the other hand, some background
medications may confound and/or obscure a therapeutic
response. For example, excluding corticosteroids beyond
a certain dose or requiring a stable background dose of
corticosteroids would seem prudent. It was agreed that
prednisone or its equivalent at410 mg/day in a stable regi-
men might be acceptable in trials of the skin, joints or lungs,
but higher doses might obscure results or increase the risk
of scleroderma renal crisis. Excluding calcium channel
blockers (CCBs), angiotensin-converting enzyme (ACE)
inhibitors or selective serotonin reuptake inhibitors
(SSRIs) in trials of RP would be necessary, as these all de-
crease vascular reactivity. The use of background im-
munosuppressants in a trial of immunosuppressants
could obviously confound results, although a trial allowing
background immunosuppressants might be considered if a
particular therapeutic intervention might add to or enhance
the effect of the background immunosuppression [1922].
(xiii) Concomitant diseases need to be considered (high
quality). Some diseases may interfere with assessment of
the intervention and therefore should be excluded. For
example, uncontrolled hypertension should be excluded
in a protocol oriented towards cardiac or renal involve-
ment. Malignancy, liver disease or diabetes should be
excluded if one is considering the need for significant
follow-up, if a drug is metabolized by the liver or if out-
come measures may be interfered with by the presence of
a polyneuropathy (e.g. in diabetics). On the other hand,
allowing multiple concomitant diseases will allow better
generalization, as the patients are more likely to be
those found in the general population. Further, allowing
multiple concomitant diseases will make recruitment
easier. In general, however, allowing unstable concomi-
tant illnesses will interfere with the ability to measure out-
comes and thus will increase the probability of a false
result.
(xiv) Baseline disease severity might also be considered
(moderate quality). End-stage patients with severely
damaged organs are very unlikely to be able to improve
sufficiently to be measurable in a short (1 year) study.
Some authorities suggest the use of quantitative or even
qualitative nailfold capillaroscopy as such a measure of
severity [28]. The Medsger severity scale has also been
used to establish severity [29]. One issue here is the dif-
ficulty of separating damage (irreversible to a large extent)
from activity (frequently reversible), but there is no agree-
ment on how this can be done at the present time.
Outcomes
(xv) The primary outcome measures should be validated
measures (high quality).
This is exemplified by adherence to standards such as the
OMERACT filters of truth, discrimination and feasibility
[30]. Although it was recognized that there is a relative
paucity of validated outcome measures in SSc, it was
agreed that carefully defined and validated primary out-
come measures should be used, and there are, in fact, a
number of validated measures available in SSc [3135].
For example, in a therapeutic trial aimed at the skin, the
validated modified Rodnan skin score should be used and
carefully defined upper and lower limits of the skin score
should be stated in the inclusion criteria [36, 37]. This is
needed to avoid floor or ceiling effects (see the PTCs on
skin for further discussion).
(xvi) If a therapeutic intervention might affect other organ
systems in addition to the primary one, those organ sys-
tems also need to be carefully defined in the inclusion
criteria (moderate quality). For example, in a trial where
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the skin is the primary measure, the acceptable pulmon-
ary function tests [e.g. forced vital capacity (FVC), a vali-
dated measurement in SSC)] should be defined if the
therapeutic intervention might affect the lungs as well
[37, 38].
If the contemplated primary outcome has not been vali-
dated, it might be necessary to develop and/or validate
such a test as a preliminary to a phase 3 trial. This devel-
opment could occur during a phase 12B trial while sim-
ultaneously using another valid and appropriate outcome
[e.g. validating high-resolution CT (HRCT) of the lungs
while using the FVC during phase 12B].
Other organ system manifestations that might confound
the primary outcome or might result in dropout before
study completion should be considered. For example, a
trial of the lungs should exclude patients with significant
cardiac involvement or myositis, as those illnesses may
confound results or, if severe, the patient might die before
completing the trial.
While an overall estimation of involvement by SSc, such
as the DAS in RA, may be appropriate, such a combined
score might best be used in a therapeutic trial of an inter-
vention that has very widespread effects. An example of
such a therapeutic approach would be stem cell trans-
plantation in SSc [38]. Thus far the EULAR Scleroderma
Trials and Research group (EUSTAR) activity measure is
the closest to validation as a combined measure and sev-
eral others are being considered [39].
Analysis
(xvii) When analysing a clinical trial, prespecified analyses
are important (high quality). Without prespecification of
analyses, a trial may simply become a fishing expedition
where multiple analyses are done and only the one best
fitting the desired outcome is published. Obviously such
an approach is not appropriate or credible.
(xviii) The patient population needs to be described in suf-
ficient detail to define the type of patient for whom the
intervention would be applicable (high quality). For ex-
ample, age, gender distribution, disease duration, organ
involvement, concomitant diseases and concomitant
medications all might be considered.
(xix) Depending on the phase of the study, power analysis
to define the number of patients needed to have confi-
dence in the results would be appropriate (moderate qual-
ity). Thus predefining the probability of a false positive and
false negative result is helpful in understanding the mean-
ing of the result. Power analyses should be done for all
phase 3 and most phase 2 trials, but are not always
necessary if the result is aimed at understanding future
study design or getting a sense of the safety of a treat-
ment. Likewise, power analyses are not needed if one is
simply seeking a biological response without clinical cor-
relates or a pharmacokinetic result.
(xx) If comparisons between groups are desired, statistical
tests should consider the distribution of results (e.g.
parametric versus non-parametric distributions), charac-
teristics of the outcomes (continuous, ordinal, dichotom-
ous) and how to deal with the inevitable missing results (a
strategy to account for missing data) (high quality) [40].
Sometimes the distribution of results may not be known,
but considering these possibilities was felt by all to be
likely to enhance the credibility of the outcomes derived
from the study. Appropriate tests could include analysis of
variance, analysis of covariance, linear or logistic regres-
sion, generalized estimating equations, survival analyses
etc.
(xxi) Considerations of how to summarize and examine
adverse events should be undertaken (high quality).
Thus, for example, one might wish to enumerate the
adverse events or consider percentage occurrence or
rates, when appropriate.
(xxii) As serious adverse events (e.g. death or hospitaliza-
tion) are always of concern, they should be carefully
described.
Conclusion
Using a literature review, Delphi exercises and a consen-
sus-driven approach, a general set of PTCs when doing
clinical trials for SSc is described. We hope that the PTCs
presented here will help to clarify these issues and give
some guidance for clinical trial design.
Rheumatology key messages
. Placebo-controlled trials using appropriate back-
ground therapy are needed in SSc.
. Well-defined SSc and uniform patient selection will
improve outcomes.
. Validated SSc outcomes and predetermined ana-
lyses are required.
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